Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
Incyte Corp.
INCYUS
$
0.00
0.00%
After Hours
$
61.04
After Hours Volume:
31.04K
| Close | Chg | Chg % |
|---|---|---|
| $61.04 | -0.47 | -0.76% |
Volume: 1.51M
65 Day Avg: 1.68M
60.61
Day Range
61.76
60.61
52 Week Range
86.29
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
INCY Overview
Key Data
- Open $61.34
- Day Range 60.61 - 61.76
- 52 Week Range 60.61 - 86.29
- Market Cap $13.72B
- Shares Outstanding 223.09M
- Public Float 219.51M
- Beta 0.67
- Rev. per Employee $1.493M
- P/E Ratio 42.17
- EPS $1.45
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 6.87M 05/31/23
- % of Float Shorted 3.13%
- Average Volume 1.68M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 21
Full Ratings
Recent News
Incyte downgraded to in line from outperform at Evercore ISI
Incyte gets FDA approval for a new vitiligo treatment
Incyte Corp. said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune disease that can cause patients to ...
Biotech and Pharma Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises.
FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
Eli Lilly & Co. and Incyte said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricit...
Eli Lilly shares jump 1.7% premarket
FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients
A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new , which was...
3 Biotech Stocks Poised to Skyrocket
on StockNews.com
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
on Benzinga.com
JMP Securities Sticks to Their Buy Rating for Incyte (INCY)
on TipRanks.com
Goldman Sachs Reaffirms Their Buy Rating on Incyte (INCY)
on TipRanks.com
Vanguard Health Care Fund Adds to Merck Stake, Cuts Back GSK Position
Vanguard Health Care Fund Adds to Merck Stake, Cuts Back GSK Position
on GuruFocus.com
Why Incyte Shares Are Falling Today
on Benzinga.com
Earnings Outlook For Incyte
on Benzinga.com
Incyte Corp.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Seagen Inc. | $36.51B | |
| Alnylam Pharmaceuticals Inc. | $23.71B | |
| Novozymes A/S Series B | kr.94.18B | |
| Bio-Techne Corp. | $12.48B | |
| BioMarin Pharmaceutical Inc. | $17.32B | |
| 10x Genomics Inc. | $6.31B | |
| Incyte Corp. | $13.72B | |
| Bloomage BioTechnology Corp. Ltd. A | ¥34.37B | |
| CureVac N.V. | $2.35B |